
	Celgene Corporation&nbsp;is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in&nbsp;Summit, New Jersey. The company&#39;s major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe&nbsp;erythema nodosum leprosum&nbsp;(&quot;ENL&quot;), as well as in combination with dexamethasone for patients with newly diagnosed&nbsp;multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy.
